Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Com-COV stage 2: heterologous versus homologous COVID-19 booster schedules
ISRCTN27841311Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of elasomeran, NVX-CoV2373, ChAdOx1 nCoV-19 and tozinameran in coronavirus disease 2019 (COVID-19) (12 cohorts), sponsored by University of Oxford. Primary endpoint: Anti-spike immunoglobulin response at Day 28. Started Apr 2021; status: completed.
02
Drugs
elasomeranNVX-CoV2373ChAdOx1 nCoV-19tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN27841311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27841311.